Biotech Acquisition Co Watch

from 8-K 4 pages Promissory Note

from 8-K 3 pages Promissory Note

from 8-K 6 pages Termination and Release Agreement

from S-4/A 15 pages Registration Rights Agreement

from S-4/A 50 pages Common Stock Purchase Agreement

from S-4/A 2 pages Blade Therapeutics, Inc. (The “Company”) Would Like to Amend the Terms of Your Employment (And Your Underlying Offer Letter Dated September 30, 2016 (The “Offer Letter”)) as Set Forth in This Letter (This “Agreement”) to Reflect the Following Adjustments to Your Compensation, Which Will Be Subject to the Consummation of the Transactions Currently Contemplated Involving the Acquisition of the Company by a Special Purpose Acquisition Company in Order to Complete a Public Offering of Its Common Stock, Following Such Transaction the Company or Its Successor (A) Is Required to File Periodic Reports Pursuant to Section 12 of the Securities Exchange Act of 1934, as Amended, and (B) the Company’s Common Stock (Or the Successors Common Stock) Is Listed on One or More National Securities Exchanges or Is Quoted on NASDAQ or a Successor Quotation System (The “Spac Transaction”) and Shall Be Deemed Effective Upon January 1, 2022 (The “Effective Date”) Following the Consummation of the Spac Transaction (The “Closing”). for Purposes Hereof, All References to the Company Shall Include References to Any Successor of the Company Following the Closing

from S-4/A 2 pages Blade Therapeutics, Inc. (The “Company”) Would Like to Amend the Terms of Your Employment (And Your Underlying Offer Letter Dated April 19, 2017 (The “Offer Letter”)) as Set Forth in This Letter (This “Agreement”) to Reflect the Following Adjustments to Your Compensation, Which Will Be Subject to the Consummation of the Transactions Currently Contemplated Involving the Acquisition of the Company by a Special Purpose Acquisition Company in Order to Complete a Public Offering of Its Common Stock, Following Such Transaction the Company or Its Successor (A) Is Required to File Periodic Reports Pursuant to Section 12 of the Securities Exchange Act of 1934, as Amended, and (B) the Company’s Common Stock (Or the Successors Common Stock) Is Listed on One or More National Securities Exchanges or Is Quoted on NASDAQ or a Successor Quotation System (The “Spac Transaction”) and Shall Be Deemed Effective Upon January 1, 2022 (The “Effective Date”) Following the Consummation of the Spac Transaction (The “Closing”). for Purposes Hereof, All References to the Company Shall Include References to Any Successor of the Company Following the Closing

from S-4/A 2 pages Blade Therapeutics, Inc. (The “Company”) Would Like to Amend the Terms of Your Employment (And Your Underlying Offer Letter Dated February 1, 2021 (The “Offer Letter”) as Set Forth in This Letter (This “Agreement”) to Reflect the Following Adjustments to Your Compensation, Which Will Be Subject to the Consummation of the Transactions Currently Contemplated Involving the Acquisition of the Company by a Special Purpose Acquisition Company in Order to Complete a Public Offering of Its Common Stock, Following Such Transaction the Company or Its Successor (A) Is Required to File Periodic Reports Pursuant to Section 12 of the Securities Exchange Act of 1934, as Amended, and (B) the Company’s Common Stock (Or the Successors Common Stock) Is Listed on One or More National Securities Exchanges or Is Quoted on NASDAQ or a Successor Quotation System (The “Spac Transaction”) and Shall Be Deemed Effective Upon January 1, 2022 (The “Effective Date”) Following the Consummation of the Spac Transaction (The “Closing”). for Purposes Hereof, All References to the Company Shall Include References to Any Successor of the Company Following the Closing

from S-4/A 2 pages Blade Therapeutics, Inc. (The “Company”) Would Like to Amend the Terms of Your Employment (And Your Underlying Offer Letter Dated July 7, 2016 (The “Offer Letter”)) as Set Forth in This Letter (This “Agreement”) to Reflect the Following Adjustments to Your Compensation, Which Will Be Subject to the Consummation of the Transactions Currently Contemplated Involving the Acquisition of the Company by a Special Purpose Acquisition Company in Order to Complete a Public Offering of Its Common Stock, Following Such Transaction the Company or Its Successor (A) Is Required to File Periodic Reports Pursuant to Section 12 of the Securities Exchange Act of 1934, as Amended, and (B) the Company’s Common Stock (Or the Successors Common Stock) Is Listed on One or More National Securities Exchanges or Is Quoted on NASDAQ or a Successor Quotation System (The “Spac Transaction”) and Shall Be Deemed Effective Upon January 1, 2022 (The “Effective Date”) Following the Consummation of the Spac Transaction (The “Closing”). for Purposes Hereof, All References to the Company Shall Include References to Any Successor of the Company Following the Closing

from S-4/A 3 pages 30 September 2016 Dear Felix, Congratulations! On Behalf of Blade Therapeutics, Inc. (The “Company”), I Am Pleased to Set Forth Below the Terms of Your Employment With the Company. Should You Accept Our Offer

from S-4/A 3 pages 19 April 2017 Dear Prabha, Congratulations! On Behalf of Blade Therapeutics, Inc. (The “Company”), I Am Pleased to Set Forth Below the Terms of Your Employment With the Company. Should You Accept Our Offer

from S-4/A 4 pages February 1, 2021 Jean-Frédéric Viret, PH.D. Dear Jean

from S-4/A 4 pages Blade Therapeutics, Inc. July 18, 2016

from S-4 16 pages This Sublease (This “Sublease”) Is Dated for Reference Purposes as of October 1, 2019, and Is Made by and Between Blade Therapeutics, Inc., a Delaware Corporation (“Sublessor”), and Applied Molecular Transport Inc., a Delaware Corporation (“Sublessee”). Sublessor and Sublessee Hereby Agree as Follows

from S-4 5 pages First Amendment to Lease

from S-4 64 pages Britannia Life Science Center Lease

from 8-K 32 pages Form of Amended and Restated Registration Rights Agreement

from 425 32 pages Form of Amended and Restated Registration Rights Agreement

from 425 25 pages Form of Subscription Agreement

from 8-K 25 pages Form of Subscription Agreement